Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model
PR Newswire PR Newswire•May 18, 2020 - Wize Pharma owns 8.9% of Bonus BioGroup
- MesenCure reduced fluid in lungs by 47% and increased blood lymphocyte counts
HOD HASHARON, Israel, May 18, 2020 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that on May 13, 2020, Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns an 8.9% equity stake, reported preliminary pre-clinical results in an animal model for its novel drug product candidate MesenCure, specifically developed to treat life-threatening acute respiratory distress in COVID-19 patients and pneumonia patients. Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.
Bonus BioGroup reported that it is developing MesenCure specifically to treat the respiratory symptoms of COVID-19 patients by reducing the inflammatory process in the respiratory system, allowing the injured lungs to recover. MesenCure consists of activated mesenchymal cells (MSCs) that are isolated from the adipose tissue of healthy donors. Following intravenous transfusion, the activated cells are expected to reach the lungs and act to reduce inflammation, and alleviate respiratory and other symptoms.
This preclinical study was conducted on an animal model suffering from severe respiratory distress symptoms similar to those of COVID-19 patients, including massive infiltration of immune cells to the lungs, a marked increase in fluid in the lungs, and a decrease in blood lymphocytes cell counts.
Treatment with MesenCure reduced Pulmonary edema (fluid) in the lungs by 47% compared to untreated subjects, and demonstrated the ability to significantly increase blood lymphocyte counts, which play a key role in fighting viruses. According to Bonus BioGroup, these results indicate the ability of MesenCure to relieve acute pneumonia and to alleviate life-threatening lymphopenia in COVID-19 patients.
Bonus BioGroup has more than a decade of MSC-related experience, patented technologies, and in-house MSC manufacturing capacity based on the development of its lead clinical stage BonoFill™, a tissue-engineered bone graft product.
MesenCure may be useful for treating a variety of indications, such as lower respiratory tract infections, acute respiratory distress syndrome, asthma, and chronic obstructive pulmonary disease. According to the Forum of International Respiratory Societies, worldwide more than 1 billion people are suffering from inflammatory diseases of the lower respiratory tract worldwide, which cause an estimated 7.5 million deaths each year, and are the third leading cause of death in Europe, not including COVID-19 mortality data.
"We are pleased to see the positive results reported by Bonus BioGroup, based on its MSC-related experience with BonoFill, on MesenCure in this preclinical study." stated Noam Danenberg, CEO of Wize. https://finance.yahoo.com/news/wize-pharmas-strategic-transaction-partner-130000128.html